Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease.
Gastroenterol Clin North Am
; 51(2): 283-298, 2022 06.
Article
in En
| MEDLINE
| ID: mdl-35595415
ABSTRACT
Over the past 2 decades, there have been incredible advances in the pharmacotherapeutic options for the treatment of patients with moderately to severely active Crohn's disease. Despite the leaps and strides in safety, efficacy, and mechanistic specificity of treatment targets, a significant portion (up to â¼20-50%) of patients have refractory Crohn's disease ± concomitant rheumatologic disease/extraintestinal manifestations for which existing biologic and small molecule therapies are ineffective. In this review, we will explore the available evidence for the use of dual advanced therapies (combination of biologic and/or small molecule therapies) and novel pharmacotherapies in phase 2 to 3 clinical trials.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biological Products
/
Crohn Disease
Limits:
Humans
Language:
En
Journal:
Gastroenterol Clin North Am
Journal subject:
GASTROENTEROLOGIA
Year:
2022
Document type:
Article